Compare PepsiCo, Inc. (PEP) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
PepsiCo, Inc. vs Travere Therapeutics Inc. Common Stock — how do they compare? PepsiCo, Inc. trades at $130 (market cap $173.48B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: PepsiCo, Inc. is far larger — about 35.5× Travere Therapeutics Inc. Common Stock's market cap, and PepsiCo, Inc. pays a 4.65% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold PepsiCo, Inc. for 108 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| PEP | TVTX | |
|---|---|---|
Market Cap | $173.48B | $4.88B |
Volume | 11,774,872 | 1,668,577 |
Sector | Consumer Staples | Health |
52-Week High | $170.44 | $67.52 |
52-Week Low | $123.64 | $26.79 |
Typical Hold Time | 108 Days | 0 Days |
Enterprise Value | $214.19B | $5.01B |
Dividend Yield | 4.65% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PepsiCo (PEP) trades at $129.27, up 2.01% with strong earnings momentum as the company has beaten EPS estimates for four consecutive quarters. The stock shows bearish technical signals but maintains solid fundamentals with $93.93B revenue and 11.09% net margin. Recent news highlights price adjustments on snack products and sponsorship changes, while analysts maintain a cautious outlook with 67.4% hold ratings.
PEP offers stable dividend income and consistent profitability, though near-term headwinds include pricing sensitivity and competitive pressures. The consensus price target of $142.38 suggests 10% upside potential, but technical weakness and mixed sentiment warrant careful monitoring of North American performance in upcoming earnings.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About PepsiCo, Inc.
PepsiCo is one of the largest food and beverage companies globally. It makes, markets, and sells a slew of brands across the beverage and snack categories, including Pepsi, Mountain Dew, Gatorade, Doritos, Lays, and Ruffles. The firm uses a largely integrated go-to-market model, though it does leverage third-party bottlers, contract manufacturers, and distributors in certain markets. In addition to company-owned trademarks, Pepsi manufactures and distributes other brands through partnerships and joint ventures with companies such as Starbucks. The firm segments its operations into five primary geographies, with North America (comprising Frito-Lay North America, Quaker Foods North America, and North America beverages) constituting around 60% of consolidated revenue.
Read more on PEP →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
